GLP-1 Medicines for Prediabetes: Who Qualifies, What Changes, and the Lifestyle Alternative

A woman in her fifties sits in an exam room holding a printout with one number circled: 6.1. Her doctor calls it prediabetes. Her sister-in-law calls it a reason to ask about the injection everyone is talking about. Both of them have a point, and neither has the whole picture.

Search interest in ozempic for prediabetes has climbed steadily, and as of September 2026 the reason is not a new approval. It is a collision of three things: a mature body of trial data showing that semaglutide returns many people with prediabetes to normal blood sugar, a steady stream of social videos in which people describe getting a prescription “just for prediabetes,” and an ongoing debate among diabetes specialists about whether a diagnosis that touches roughly one in three American adults should ever be treated with a weekly injection.

This piece sorts the label from the hype, grades the evidence, and takes the lifestyle alternative as seriously as the medicine.

Can you take Ozempic for prediabetes if you're not diabetic?

The short version: a clinician can prescribe it, but the label does not support it. Ozempic is the brand of semaglutide approved in the United States to improve blood sugar in adults with type 2 diabetes and to lower cardiovascular risk in those who also have heart disease. Prediabetes appears nowhere on that label. Using a medicine for a condition outside its approval is called off-label prescribing, which is legal, common, and entirely the prescriber’s judgment call.

The confusion comes from a quirk of naming. Semaglutide is sold under two brand names by the same manufacturer. Ozempic is the diabetes version. Wegovy is the weight-management version, approved for adults with a body mass index (BMI, a weight-to-height ratio) of 30 or more, or 27 or more with at least one weight-related health problem. Prediabetes is widely regarded by clinicians as one of those weight-related problems, alongside high blood pressure and abnormal cholesterol. So a person with prediabetes and a BMI in that range may be a candidate for semaglutide under the Wegovy label, even though Ozempic itself is not indicated for them.

That distinction matters in practice. The same molecule, prescribed under the weight-management label, sits on firmer ground than the diabetes brand prescribed off-label for a diagnosis it was never studied for as a primary endpoint. Prediabetes without excess weight is a different story: there, no GLP-1 medicine has an approved indication, and the evidence base is thin.

Semaglutide belongs to a class called GLP-1 receptor agonists, medicines that mimic a gut hormone released after meals. Everything that follows about how they work, what the trials show, and what to watch for applies to the molecule regardless of the name on the pen. Whether that molecule is right for a specific person with a specific A1C is a conversation for the exam room, not the comment section.

What prediabetes actually is, in numbers

Prediabetes is a laboratory diagnosis, not a feeling. Most people have no symptoms at all, which is why the CDC estimates that more than 8 in 10 American adults who have it do not know. Roughly 98 million adults meet the criteria, a little over a third of the adult population.

Three tests define it. Hemoglobin A1C, a measure of average blood sugar over the previous two to three months, falls between 5.7 and 6.4 percent. Fasting plasma glucose, taken after at least eight hours without food, lands between 100 and 125 mg/dL. A two-hour oral glucose tolerance test, in which blood sugar is measured after drinking a standard sugary solution, reads between 140 and 199 mg/dL. Cross any of those thresholds upward and the diagnosis becomes type 2 diabetes.

Underneath the numbers is insulin resistance: the body’s cells respond sluggishly to insulin, the hormone that moves sugar out of the bloodstream, so the pancreas compensates by producing more. For years that compensation works. Prediabetes is the stage where it begins to fail, and blood sugar starts drifting upward after meals and eventually in the fasting state too.

The trajectory is not fixed. Without intervention, the CDC notes that many people with prediabetes progress to type 2 diabetes within five years, though estimates vary with age, weight, and how high the numbers already are. A person at 5.7 percent with modest excess weight sits in a very different place from someone at 6.4 percent with a strong family history. Guidelines treat the higher end of the range, especially with a BMI over 35 or a history of gestational diabetes, as a signal for more aggressive prevention.

Two facts anchor everything else in this article. First, prediabetes reverses in a meaningful share of people who lose 5 to 7 percent of body weight. Second, it is a risk state, not a disease with complications of its own, which is why the bar for medicine is set differently than it would be for diabetes itself.

What changed recently

Nothing on the regulatory front, which is the most important recent fact. As of this writing, no GLP-1 medicine in the United States carries a prediabetes indication. The trend is being driven by accumulating evidence and cultural momentum, not by a label change.

The evidence timeline runs like this. In February 2021, the STEP 1 trial published in the New England Journal of Medicine reported that adults with obesity but without diabetes lost an average of 14.9 percent of body weight over 68 weeks on weekly semaglutide, against 2.4 percent on placebo. Buried in that paper was a number that fueled everything since: among participants who had prediabetes at enrollment, 84 percent had normal blood sugar by the end of the trial, compared with 48 percent of those on placebo. A 2022 secondary analysis of the STEP program in Diabetes Care confirmed the pattern across trials.

In November 2023, the SELECT trial reported that semaglutide reduced major cardiovascular events by 20 percent in adults with established heart disease and overweight or obesity but without diabetes. In March 2024 the FDA added that cardiovascular risk reduction to the Wegovy label. Roughly two-thirds of SELECT participants had prediabetes at baseline, which is why the trial keeps surfacing in this conversation.

Tirzepatide, a related medicine that activates two gut-hormone receptors, added fuel in late 2024 when a three-year extension of its SURMOUNT-1 obesity trial reported that participants with prediabetes were far less likely to progress to type 2 diabetes than those on placebo, a relative reduction of around 94 percent.

Meanwhile the American Diabetes Association’s annual Standards of Care have continued to name intensive lifestyle intervention as the foundation of prevention and to list metformin as a medication to consider in higher-risk adults, while stopping short of recommending GLP-1 medicines for prediabetes itself. That gap between what trials show and what guidelines endorse is exactly where the current search surge lives.

How GLP-1 medicines work in a body with prediabetes

Glucagon-like peptide-1, or GLP-1, is a hormone the small intestine releases within minutes of eating. It tells the pancreas to release insulin in proportion to the glucose arriving, suppresses glucagon (the hormone that raises blood sugar), slows the stomach’s emptying so carbohydrates trickle rather than flood into the blood, and signals the brain’s appetite centers that a meal is underway. Natural GLP-1 is broken down within a couple of minutes. Semaglutide is engineered to resist that breakdown and stay active for about a week.

Each of those actions touches a piece of prediabetes. The glucose-dependent insulin release means the pancreas works harder only when sugar is high, which is why semaglutide alone rarely causes dangerous low blood sugar in people not taking insulin or sulfonylureas. The glucagon suppression trims the liver’s overnight sugar output, the mechanism behind elevated fasting glucose. The slowed gastric emptying flattens the after-meal spikes that an oral glucose tolerance test is designed to catch.

The biggest effect, though, is indirect. Appetite suppression leads to sustained weight loss, and weight loss of 10 to 15 percent restores insulin sensitivity in muscle and liver more effectively than any direct pancreatic effect. Researchers who dissected the STEP data found that the return to normal blood sugar tracked closely with how much weight participants lost, which suggests the medicine is largely working through the same pathway a successful lifestyle program uses, only faster and with less reliance on willpower.

This has a practical implication. If the benefit runs mostly through weight, then the benefit is expected to last only as long as the weight stays off, whether that is achieved with continued medicine or with sustained habit change. It also explains why a person with prediabetes and a normal BMI is a poor fit for the drug: there is far less weight to lose, and the direct glucose effects alone have not been shown to prevent diabetes in that group.

None of this makes GLP-1 medicines a shortcut around metabolism. They are a tool that leans hard on one lever, appetite, and lets physiology do the rest.

What the evidence actually says, graded by strength

Evidence is not one thing. Randomized controlled trials, in which participants are assigned by chance to a treatment or placebo, sit at the top because they minimize bias. Observational studies, which track what happens to people who chose a treatment, come next. Expert opinion and mechanistic reasoning sit at the bottom. Here is where each claim about semaglutide for prediabetes lands.

Strong (randomized trial, secondary outcome): Semaglutide returns a large majority of adults with obesity and prediabetes to normal glucose while they take it. STEP 1’s 84 percent versus 48 percent is a real, prespecified secondary analysis in a rigorous trial. The caveat is in the wording: prediabetes was not the reason participants were enrolled, and normalization of glucose was not the primary outcome.

Strong (randomized trial, primary outcome): Semaglutide produces roughly 15 percent average weight loss over 68 weeks in adults with obesity. This is the best-established fact in the field.

Moderate: Semaglutide reduces cardiovascular events in adults with existing heart disease and excess weight. SELECT was large and well run, but participants had established cardiovascular disease; the result does not automatically extend to a 48-year-old with prediabetes and no heart history.

Moderate to weak: Semaglutide prevents the eventual diagnosis of type 2 diabetes. No semaglutide trial has been designed with diabetes prevention as its primary endpoint over many years. The tirzepatide three-year data are encouraging but come from a different molecule and, again, a trial designed around weight.

Weak: GLP-1 medicines help prediabetes in people of normal weight. Essentially untested.

Strong (randomized trial, primary outcome, long follow-up): Intensive lifestyle intervention prevents or delays type 2 diabetes. The Diabetes Prevention Program randomized more than 3,000 adults with prediabetes and found a 58 percent reduction in new diabetes over about three years, with benefits still measurable more than a decade later.

Read those grades together and a fair summary emerges: the medicine clearly fixes the number while you take it; lifestyle change has the longest track record of changing the destination.

Ozempic vs Wegovy vs metformin vs lifestyle: a side-by-side

People searching this topic are usually weighing four paths. The table lays out what is known about each for a person with prediabetes and excess weight. Dosing is deliberately excluded; that belongs to a prescriber.

Option	US approval status for prediabetes	Best evidence for glucose	Typical weight effect	Main trade-offs
Ozempic (semaglutide)	Not approved; label is type 2 diabetes	Diabetes trials only; prediabetes use is off-label	Meaningful, but diabetes-dose trials show less than Wegovy-dose trials	GI side effects; weekly injection; benefit requires continued use
Wegovy (semaglutide)	Not approved for prediabetes; approved for weight management (BMI 30+, or 27+ with a weight-related condition) and cardiovascular risk reduction	84% of prediabetes participants reached normal glucose vs 48% placebo (STEP 1, secondary outcome)	About 15% average loss at 68 weeks	Same GI profile; weight regain after stopping; cost and coverage hurdles
Metformin	Not approved for prediabetes; guideline-supported as an option in higher-risk adults	31% reduction in progression to diabetes over ~3 years (DPP, primary outcome)	Modest, around 2% of body weight	Oral; decades of safety data; GI upset; less effective after age 60
Structured lifestyle program	Recommended first-line by CDC and ADA	58% reduction in progression over ~3 years, 71% in adults 60+ (DPP, primary outcome)	Target of 7% loss; averaged 5-7% at one year	Requires sustained effort and support; effect fades if habits lapse

Two things jump out. The lifestyle row is the only one with a decades-long randomized record for the outcome that actually matters, new diabetes. And the semaglutide rows show the largest short-term effect on both weight and glucose, but through a secondary lens. Metformin sits in between: a smaller effect, a very long safety history, and a pill rather than a pen.

The honest reading is not “which wins” but “which fits.” A 62-year-old with an A1C of 5.8 percent and a BMI of 28 is a textbook lifestyle candidate. A 45-year-old with an A1C of 6.3 percent, a BMI of 36, sleep apnea and a parent who developed diabetes at 50 is a person for whom a clinician might reasonably discuss medicine alongside, not instead of, the same program.

What A1C level is needed for Ozempic, and who qualifies for semaglutide for prediabetes?

There is no A1C that unlocks Ozempic, because Ozempic’s approval is tied to a diagnosis, not a number. Type 2 diabetes is diagnosed at an A1C of 6.5 percent or higher, so a person at 6.4 percent does not meet the label and a person at 6.5 percent does. That single decimal point is the whole of the official answer, and it is why so many people with prediabetes find that their clinician steers them toward Wegovy instead.

Wegovy’s qualifying criteria are about weight rather than sugar. The label specifies a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition. The label lists high blood pressure, type 2 diabetes and abnormal cholesterol as examples; most clinicians consider prediabetes, sleep apnea and fatty liver disease to belong on that list as well. For adults with established cardiovascular disease and a BMI of 27 or higher, the 2024 label expansion adds a second qualifying route regardless of glucose.

So for practical purposes, a person with prediabetes qualifies for semaglutide under the weight-management label when two things are true: their BMI meets the threshold, and their clinician documents prediabetes as the weight-related condition. Their A1C could be 5.7 or 6.4; the label does not distinguish.

Guidelines add nuance the label lacks. The American Diabetes Association flags certain features as reasons to consider pharmacotherapy for prevention more seriously: BMI of 35 or higher, age under 60, a history of gestational diabetes, and A1C at the upper end of the prediabetes range. Those are the same features that predict faster progression to diabetes. A clinician weighing semaglutide for prediabetes is likely to be more persuaded by a patient who ticks several of those boxes than by one who ticks none.

Exclusions matter as much as inclusions. A personal or family history of medullary thyroid cancer or a syndrome called MEN 2, a prior episode of pancreatitis, and pregnancy or plans for pregnancy are reasons a prescriber may decline. Those histories should be on the table before any conversation about eligibility begins.

Is metformin or Ozempic better for prediabetes?

Better at what, and for whom. The two medicines have never been compared head to head in a prediabetes trial, so the honest answer is assembled from separate studies with different designs.

Metformin’s case rests on the Diabetes Prevention Program, a randomized trial funded by the NIH that enrolled 3,234 adults with prediabetes in the late 1990s. Over an average of nearly three years, metformin reduced new diagnoses of type 2 diabetes by 31 percent compared with placebo. The effect was strongest in people under 60 and in those with a BMI of 35 or higher; in participants over 60 it was statistically indistinguishable from placebo. Follow-up studies tracked participants for more than 15 years and found the benefit persisted, though it narrowed. Metformin has been in use since the 1950s, is taken by mouth, and its side effects, mostly stomach upset and a small long-term risk of vitamin B12 deficiency, are well mapped.

Semaglutide’s case rests on weight. It produces roughly seven times the weight loss of metformin and, as a result, normalizes glucose in a much higher share of people while they take it. Against that, its prediabetes evidence is secondary, its follow-up shorter, its side effects more frequent early on, and it requires a weekly injection.

Guideline bodies have landed on a clear if unsatisfying position: metformin is the medication to consider for diabetes prevention, particularly in the higher-risk subgroups above; GLP-1 medicines are appropriate for treating obesity, and prediabetes may be one of the reasons obesity treatment is warranted. In other words, the question “metformin or Ozempic” often resolves into “is my main problem elevated glucose, or is it excess weight that is driving elevated glucose?”

Both are off-label for prediabetes specifically. Either choice, and the choice to use neither, belongs to the prescribing clinician who knows the patient’s kidney function, heart history, medication list and pregnancy plans. What a magazine can say is that the evidence does not crown a winner, and that anyone promising one is selling something.

What changes in the first months: effects and side effects

People who start semaglutide describe the same thing in the first weeks, almost word for word: the food noise goes quiet. The running internal commentary about the next meal fades, portions shrink without effort, and the fullness after eating arrives earlier and lasts longer. This is the appetite effect doing what the trials say it does.

The stomach is where most of the early trouble lives. In STEP 1, nausea affected about 44 percent of participants at some point, diarrhea about 32 percent, vomiting about 24 percent and constipation about 23 percent, against much lower rates on placebo. Most episodes were mild to moderate and clustered around the periods when the prescriber was stepping the medicine up. About 4.5 percent of participants stopped because of gastrointestinal effects. Fatigue, headache and burping are common enough to mention.

Blood sugar typically improves before much weight comes off, because the direct effects on insulin and glucagon act within days. Weight loss itself follows a curve: fastest in the first four to five months, then slowing, then plateauing somewhere between 12 and 16 months in the trials. An A1C recheck at three months usually shows movement; a person who started at 6.2 percent often finds themselves back under 5.7 percent by the second or third test.

Less common effects deserve a clear sentence each. Gallbladder problems, including gallstones, occur more often with rapid weight loss from any cause and were seen in about 2.6 percent of STEP 1 participants. Pancreatitis, inflammation of the pancreas, is rare but serious. Dehydration from persistent vomiting or diarrhea can strain the kidneys. Low blood sugar is uncommon in people not taking insulin or sulfonylureas, but not impossible, particularly in those who stop eating much. The medicine carries a boxed warning about thyroid C-cell tumors observed in rodents; whether this applies to humans is unknown, which is why the family-history exclusions exist.

Two practical shifts that catch people off guard: alcohol tolerance often drops, and a meal that would have been ordinary can now cause real discomfort. Both fade as the body adjusts, but both are worth knowing before the first week.

What happens to prediabetes when you stop the medicine

The most consequential fact in this article is one the social videos rarely mention. When semaglutide stops, appetite returns, and for most people so does the weight, and with it the blood sugar.

The STEP 1 extension study followed participants for a year after the trial ended and all treatment was withdrawn. Those who had lost an average of 17 percent of their body weight regained about two-thirds of it within 52 weeks. Blood pressure, cholesterol and A1C tracked the regain. The improvements did not vanish entirely at one year, but the curve was headed back toward baseline.

This is not a failure of the medicine. It is the medicine working exactly as designed and then no longer being present. Obesity specialists describe GLP-1 drugs as treating a chronic condition the way blood pressure pills treat hypertension: the effect lasts as long as the treatment does. That framing is coherent for obesity. It becomes more complicated for prediabetes, a risk state with no symptoms, where the implied commitment is an indefinite weekly injection to keep a lab value in range.

Three honest paths exist for someone who has normalized their glucose on semaglutide and wants to stop. The first is to have built, during the months on medicine, the eating and activity habits that a lifestyle program teaches, so that the appetite rebound lands on a changed routine. The second is a supervised, gradual reduction with close monitoring, which some clinicians use and for which evidence is still emerging. The third is to accept long-term treatment as the price of long-term benefit, the same bargain people make with statins.

What the evidence does not support is the idea of a short course that “resets” metabolism and then leaves it fixed. No trial shows that. The Diabetes Prevention Program, by contrast, showed that people who changed how they ate and moved were still less likely to have diabetes 15 years later, even though many had regained some weight. Habits, it turns out, have a longer half-life than hormones.

Nobody should stop a prescribed medicine on the strength of a paragraph, this one included. The stopping conversation belongs with the prescriber, ideally planned from the day the first prescription is written.

Will insurance cover Ozempic for prediabetes?

Usually not for the diabetes brand, and often only with conditions for the weight-management brand. Coverage rules vary by plan, but the logic underneath them is consistent enough to explain.

Insurers anchor coverage decisions to the FDA-approved indication. Ozempic’s indication is type 2 diabetes, so a claim submitted with a prediabetes diagnosis code typically fails the plan’s criteria, no matter how the prescription is written. Some plans require documentation of a diabetes diagnosis, an A1C of 6.5 percent or above, or a trial of metformin first. A person with prediabetes will not meet those requirements.

Wegovy is a different filing. Plans that cover anti-obesity medicines generally require a BMI meeting the label threshold, documentation of a weight-related condition (which can include prediabetes), and frequently evidence of a prior attempt at lifestyle change. Many employer plans exclude weight-management medicines altogether, regardless of indication; that exclusion, not the prediabetes diagnosis, is often the real barrier.

Medicare occupies its own category. By statute, Medicare Part D excludes medicines used for weight loss, which means Wegovy prescribed for obesity is not a covered benefit even when prediabetes is part of the picture. The 2024 cardiovascular indication changed that for one group: beneficiaries with established heart disease and excess weight may be covered because the drug is then being used to reduce cardiovascular events, not for weight. Prediabetes alone does not open that door. Ozempic remains covered under Part D for diagnosed type 2 diabetes only.

A few practical realities follow. Prior authorization, a process where the prescriber justifies the prescription to the plan before it is filled, is nearly universal for these medicines. Denials can be appealed, and appeals sometimes succeed when the clinician documents multiple weight-related conditions. Coverage rules change frequently, so a plan’s answer last year may not be its answer this year.

None of this is medical advice about whether the medicine is appropriate; it is a description of how the paperwork works. The clinician’s office, which handles these authorizations daily, is the right place to ask what a specific plan requires before a prescription is written.

Compounded semaglutide and what the label does not cover

The wave of interest in ozempic for prediabetes has been accompanied by a parallel wave of semaglutide that is not Ozempic or Wegovy at all. Compounded semaglutide is a version mixed by a pharmacy rather than manufactured by the drug’s developer. It is not FDA approved, has not been tested for safety, effectiveness or quality, and the FDA has issued repeated warnings about products found to contain the wrong salt form of the molecule, the wrong concentration, or no semaglutide at all.

Federal law permits compounding in narrow circumstances, most notably during an official shortage of the approved product. Those shortage conditions have ended for semaglutide, which narrows the legal window considerably. Products marketed online as “research peptides,” “not for human consumption,” or shipped from overseas sellers fall entirely outside any medical framework. They are not medicines in the regulatory sense, are not for sale for human use, and there is no way for a buyer to verify what is in the vial.

The specific risks are not abstract. Poison control centers have logged sharp rises in calls related to semaglutide overdoses, many involving compounded or self-measured products where the person drew up the wrong volume. Symptoms have included severe vomiting, dehydration requiring intravenous fluids, and dangerously low blood sugar. Contamination and improper storage add bacterial and stability concerns that a manufactured pen does not carry.

Every reputable authority makes the same request: use only medicines prescribed by a licensed clinician and dispensed by a licensed pharmacy in their original packaging. Anyone considering semaglutide for prediabetes who is tempted by a cheaper or faster online route should treat that temptation as a signal to book an appointment, not a shortcut around one.

The label also leaves other gaps worth naming. Semaglutide has not been studied in pregnancy and is stopped ahead of planned conception. It has limited data in adults over 75. It has no data in prediabetes without excess weight. A clinician deciding to prescribe in any of those situations is exercising judgment beyond the evidence, which is their prerogative, and the patient deserves to know that is what is happening.

Common myths about prediabetes GLP-1 use, corrected

Viral claims cluster around a handful of ideas. Each one contains a grain of truth wrapped in a misunderstanding.

“Ozempic is approved for prediabetes now.” It is not, and neither is Wegovy. Wegovy is approved for weight management and cardiovascular risk reduction; prediabetes can be the weight-related condition that supports a weight-management prescription. That is a real pathway, but it is not a prediabetes approval, and no dated announcement exists to the contrary.

“A few months on it resets your metabolism for good.” The STEP 1 extension found that two-thirds of lost weight returned within a year of stopping, with glucose following. No trial shows a lasting reset after a short course.

“If your A1C is 5.7, you need medication.” Guidelines place lifestyle change first for everyone with prediabetes and reserve medication consideration for higher-risk features: A1C nearer 6.4, BMI of 35 or more, age under 60, prior gestational diabetes. The lowest end of the range is, for most people, a reason to act, not a reason to inject.

“Metformin is outdated; GLP-1s replaced it.” Metformin remains the medication guidelines name for diabetes prevention, with 31 percent risk reduction in a randomized trial designed for that purpose and long-term follow-up. GLP-1 medicines have larger short-term effects and a different evidence base. Neither replaced the other.

“Lifestyle change doesn’t work; the studies prove it.” The opposite is true. The Diabetes Prevention Program’s 58 percent reduction is the strongest prevention result in the field, and its participants averaged 5 to 7 percent weight loss, not dramatic transformation.

“It causes thyroid cancer.” The boxed warning reflects tumors in rodents at high exposures; human data have not established a link. The warning is a reason for caution and for screening family history, not a proven human risk.

“You can’t get low blood sugar without diabetes.” Uncommon but possible, particularly when food intake drops sharply. Shakiness, sweating, confusion or a racing heart while on the medicine deserve a call to the prescriber.

The pattern across these myths is the same: a real trial result, stripped of its context and its limits. Context and limits are where good decisions live.

The lifestyle alternative: what the Diabetes Prevention Program actually asked of people

“Diet and exercise” is the phrase that makes people’s eyes glaze over, partly because it sounds like moral instruction and partly because it is vague. The program that produced the best prevention data in medicine was neither.

The Diabetes Prevention Program, an NIH-funded randomized trial, gave its lifestyle group two concrete targets: lose 7 percent of starting body weight, and reach 150 minutes a week of moderate activity, the pace of a brisk walk. Participants met one on one with a coach through a 16-session core curriculum in the first six months, then monthly. They kept food and activity logs. They learned to problem-solve around holidays, travel and setbacks rather than to follow a rigid meal plan.

The results, published in 2002, showed a 58 percent reduction in new type 2 diabetes over an average of 2.8 years compared with placebo. Among participants aged 60 and older, the reduction was 71 percent. The lifestyle group averaged about 5.6 kilograms of weight loss in the first year; many later regained some, yet in follow-up studies extending past 15 years, their risk of diabetes remained roughly a quarter lower than the placebo group’s. A short, structured intervention had produced a durable shift.

The CDC translated that protocol into the National Diabetes Prevention Program, a year-long, CDC-recognized curriculum delivered in person or online through community organizations, workplaces and health systems. It follows the same targets and coaching structure. Many health plans and Medicare cover it for adults who meet the prediabetes criteria and BMI threshold, which is a rare instance of the insurance logic favoring the lower-intensity option.

Why does it work with such modest weight loss? Because insulin sensitivity in muscle improves within weeks of regular activity, independent of the scale, and because losing the first 5 to 7 percent of body weight disproportionately reduces fat stored in the liver and around organs, where it does the most metabolic harm.

The program does not exclude medicine. A person taking semaglutide who also completes a structured program is building the habits that will matter most on the day the prescription ends. Lifestyle change and GLP-1 medicines are less rivals than sequence: one changes the number quickly, the other changes what happens after.

When to see a doctor

Prediabetes itself calls for a conversation, not an emergency room. Anyone with an A1C in the 5.7 to 6.4 percent range should have a clinician confirm the result, check blood pressure and cholesterol, and lay out a plan with a follow-up test in three to six months. Adults over 35, anyone with a BMI of 25 or higher plus another risk factor, and anyone with a history of gestational diabetes should be tested if they have not been, since most people with prediabetes have never been told.

Anyone already taking semaglutide, whether as Ozempic or Wegovy, should contact the prescriber promptly for the following, and seek urgent care for the first three:

• Severe, persistent abdominal pain, especially pain that radiates to the back, with or without vomiting. This is how pancreatitis presents.
• Pain in the upper right abdomen, fever, yellowing of the skin or eyes, or clay-colored stools, which can signal gallbladder disease or bile duct blockage.
• Vomiting or diarrhea that prevents keeping fluids down for more than a day, dizziness on standing, or a sharp drop in urination, which point to dehydration and kidney strain.
• Shakiness, sweating, confusion, a racing heart or fainting, particularly if eating very little, which can indicate low blood sugar.
• A lump or swelling in the neck, hoarseness that does not resolve, or difficulty swallowing.
• Sudden changes in vision, which matter most for people who also have diabetes and existing eye disease.
• Severe constipation with bloating and inability to pass gas, a possible sign of bowel obstruction.
• Any rash, swelling of the face or throat, or difficulty breathing after an injection.

Less urgent but still worth a call: nausea that does not settle after the first weeks, unintended weight loss that feels too fast, new or worsening low mood, or a positive pregnancy test.

Never stop or adjust a prescribed medicine without speaking to the prescriber, and never start a GLP-1 medicine obtained outside a pharmacy. The person who wrote the prescription is the person who should weigh every one of these signs against the reason the medicine was started in the first place.

Frequently asked questions

Can prediabetics take Ozempic?

A clinician can prescribe it, but Ozempic is approved only for type 2 diabetes, so prediabetes use is off-label. The same medicine, semaglutide, is approved as Wegovy for weight management when BMI is 30 or higher, or 27 or higher with a weight-related condition, and prediabetes is commonly counted as one. Whether it is appropriate for a specific person depends on BMI, other health conditions and risk factors, and that decision rests with the prescribing clinician.

What A1C level is needed for Ozempic?

No A1C value unlocks Ozempic for prediabetes, because its approval depends on a diagnosis of type 2 diabetes, which begins at an A1C of 6.5 percent. Below that, a clinician who considers semaglutide would typically look at the weight-management label, which is based on BMI rather than A1C. Guidelines suggest that an A1C nearer 6.4 percent, along with BMI of 35 or more or age under 60, strengthens the case for considering medicine.

Is semaglutide for prediabetes approved by the FDA?

No. As of September 2026, neither Ozempic nor Wegovy carries a prediabetes indication. Wegovy is approved for chronic weight management and, since March 2024, for reducing cardiovascular events in adults with heart disease and excess weight. Prediabetes may be documented as the weight-related condition supporting a weight-management prescription, which is a legitimate pathway, but it is not the same as an approval for prediabetes itself.

Is metformin or Ozempic better for prediabetes?

They have never been compared head to head in prediabetes. Metformin reduced progression to diabetes by 31 percent in a randomized trial designed for that purpose and has decades of safety data. Semaglutide produces far greater weight loss and normalizes glucose in more people while taken, but its prediabetes evidence is a secondary finding from obesity trials. Guidelines name metformin as the prevention medication to consider and treat GLP-1 medicines as obesity treatments. The choice belongs to your clinician.

Will insurance cover Ozempic if you have prediabetes?

Usually not. Insurers tie Ozempic coverage to a type 2 diabetes diagnosis, and a prediabetes code typically fails their criteria. Wegovy may be covered under a plan’s anti-obesity benefit if BMI meets the label threshold and prediabetes is documented, though many plans exclude weight-management medicines entirely. Medicare Part D excludes drugs used for weight loss by law, with an exception for beneficiaries with established heart disease under the cardiovascular indication. Ask the prescriber’s office about your specific plan.

Does Wegovy for prediabetes actually prevent type 2 diabetes?

It clearly normalizes blood sugar in most people with prediabetes while they take it; STEP 1 found 84 percent reached normal glucose versus 48 percent on placebo. Whether it prevents an eventual diabetes diagnosis over many years has not been tested as a primary outcome in a semaglutide trial. A related medicine, tirzepatide, showed a large reduction in progression over three years. The evidence is encouraging but graded moderate rather than strong for long-term prevention.

What happens to blood sugar if you stop Ozempic after your A1C returns to normal?

For most people, appetite returns, weight follows, and A1C drifts back upward. In the STEP 1 extension, participants regained about two-thirds of lost weight within a year of stopping and their glucose tracked the regain. The improvements did not vanish entirely at one year but were heading toward baseline. Building lifestyle habits while on the medicine appears to soften the rebound. Any plan to stop should be made with the prescriber, not alone.

Can you reverse prediabetes without medication?

Yes, and this is the best-supported prevention strategy. The Diabetes Prevention Program found that a structured lifestyle program targeting 7 percent weight loss and 150 minutes of brisk activity weekly reduced new diabetes by 58 percent over about three years, and 71 percent in adults over 60. Follow-up beyond 15 years showed the benefit persisted. The CDC’s National Diabetes Prevention Program delivers that same curriculum through community and online programs.

What are the most common side effects of GLP-1 medicines in people with prediabetes?

Gastrointestinal effects dominate. In STEP 1, about 44 percent of participants reported nausea, 32 percent diarrhea, 24 percent vomiting and 23 percent constipation, mostly mild to moderate and concentrated in the early months. Fatigue, headache and burping are also common. Rarer but serious effects include pancreatitis, gallbladder disease, dehydration affecting the kidneys and, uncommonly, low blood sugar. Severe abdominal pain, persistent vomiting or signs of low blood sugar warrant prompt medical attention.

Is compounded semaglutide safe to use for prediabetes?

Compounded semaglutide is not FDA approved and has not been evaluated for safety, effectiveness or quality. The FDA has warned about products containing the wrong form or concentration of the molecule, and poison control centers have reported rising overdose calls linked to self-measured products. Products sold online as research peptides are not medicines and are not for human use. Semaglutide should only be used when prescribed by a licensed clinician and dispensed by a licensed pharmacy.

References

• Semaglutide Injection: MedlinePlus Drug Information
• Preventing Type 2 Diabetes: CDC
• Diabetes Prevention Program (DPP): NIH National Institute of Diabetes and Digestive and Kidney Diseases

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.